Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
Solid Biosciences Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2025.
- Period
- the fourth quarter and fiscal year ended December 31, 2025
- Result
- preliminary results
Exact text from the filing
Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, the Company expects to report cash, cash equivalents and available-for-sale securities of approximately $187.9 million as of December 31, 2025.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
Solid Biosciences Inc. issued pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock of warrant to Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others for $5.609 per Pre-Funded Warrant.
- Security
- warrant
- Shares
- pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock
- Purchaser
- Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others
- Consideration
- $5.609 per Pre-Funded Warrant
Exact text from the filing
On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.61 per share, and, to investors who so choose in lieu of Shares, pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.609 per Pre-Funded Warrant (the “ Private Placement ”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
Solid Biosciences Inc. issued 14,973,257 shares of the Company’s common stock of common stock to Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others for $5.61 per share.
- Security
- common stock
- Shares
- 14,973,257 shares of the Company’s common stock
- Purchaser
- Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others
- Consideration
- $5.61 per share
Exact text from the filing
On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.61 per share, and, to investors who so choose in lieu of Shares, pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.609 per Pre-Funded Warrant (the “ Private Placement ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Solid Biosciences Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $240.0 million (effective 2026-03-06).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional accredited investors
- Value
- approximately $240.0 million
- Effective
- 2026-03-06
Exact text from the filing
On March 6, 2026, Solid Biosciences Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a price of $5.61 per share, and, to investors who so choose in lieu of Shares, pre-funded warrants to purchase 27,807,482 shares of the Company’s common stock (the “ Pre-Funded Warrants ”), at a price of $5.609 per Pre-Funded Warrant (the “ Private Placement ”).
View on SEC.gov